Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
One of the biggest barriers manufacturers point to when it comes to the lack of widespread adoption of continuous manufacturing is uncertainty. Uncertainty of time to FDA approval relates to regulatory expectations about process validation and therapeutic equivalence when switching from batch to continuous, or developing and launching a product using continuous manufacturing and how that transition could impact their path to market. Listen to this on-demand webinar to hear from Independent Consultant, Ajaz Hussain.